1. J. Davies, M. Patel, C. Gridelli, et al., Real-world treatment patterns for patients receiving second-line and third-line treatment for advanced non-small cell lung
2. J. C. Soria, E. Felip, M. Cobo, et al., Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung
3. I. Okamoto, H. Yoshioka, S. Morita, et al., Phase III trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-naive patients with advanced non-small-cell lung
4. L. M. Sholl, D. L. Aisner, M. Varella-Garcia, et al., Multi-institutional oncogenic driver mutation analysis in lung
5. R. Rosell, E. Carcereny, R. Gervais, et al., Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer